IMMUNOHISTOCHEMICAL DETECTION OF P53 PROTEIN IN TRANSITIONAL-CELL CARCINOMA OF THE BLADDER IN CORRELATION TO DNA-PLOIDY AND PATHOHISTOLOGICAL STAGE AND GRADE
H. Alabadi et al., IMMUNOHISTOCHEMICAL DETECTION OF P53 PROTEIN IN TRANSITIONAL-CELL CARCINOMA OF THE BLADDER IN CORRELATION TO DNA-PLOIDY AND PATHOHISTOLOGICAL STAGE AND GRADE, Cancer detection and prevention, 22(1), 1998, pp. 43-50
Mutations of p53 gene have been found in a variety of human malignanci
es; however, the impact of immunohistological detection of p53 express
ion in the development and progression of TCC of the bladder is still
uncertain. Ln the present study, we investigated the p53 oncoprotein e
xpression and compared the findings to DNA ploidy and pathohistologica
l stage and grade. The study included 147 patients with transitional c
ell carcinoma of the bladder investigated between February 1981 and Se
ptember 1994. The average age of the 55 women and 92 men was 67 years
(range: 20-71 years). A total of 76 patients (52%) had stage pTa to pT
1, 35 (24%) stage pT2, 25 (17%) stage pT3, and 11 (7%) stage pT4 disea
se. Frozen sections of tumor biopsies obtained by transurethral resect
ion were immunohistochemically stained using the monoclonal antibody c
lone D0-7 (DAKO), which recognized two different epitopes for mutant a
nd wild-type p53 protein. Tumors expressing p53 in more than 10% of th
e tumor nuclei were regarded as positive. The DNA ploidy was determine
d by image analysis. Immunohistochemical detection of p53 expression w
as found in 84 (57%) of the 147 tumors examined. Positive p53 staining
was seen in grade I tumors in 10 to 25%, in grade II tumors 25 to 75%
, and in grade III up to 58% of the tumor nuclei. There was a positive
correlation between p53 expression and pathological stage (28% in pTa
, 73% in pT1-2, and 68% in pT3-4 tumors). There was no appreciable rel
ationship between DNA Ploidy and p53. Although carcinomas with p53 exp
ression had a slight tendency to be more prevalent among higher diseas
e stages and poorly differentiated transitional cell carcinoma, immuno
histochemical detection of p53 is not a valuable tool for predicting t
he outcome of patients with TCC or for identifying subgroups of patien
ts that may be at a higher risk for tumor progression.